Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY

Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.

Watch the Xeris Biopharma Holdings, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue107.274.4
Net income11.30.6
EPS (diluted, $ a share)$0.06$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+1718.0%
Revenue, year on year+44.2%
Operating margin15.8%
Source

10-Q filed with the SEC, NASDAQ: XERS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Xeris Biopharma Holdings, Inc.: key numbers

Share price
$16.70Close, Nov 16
Market cap
$3.05B
Shares outstanding
182.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Xeris Biopharma Holdings, Inc.

All →
4:32 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock

Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).

Value
$312K
Shares
25,000
Price
$12.49
Holding change
-1.6%
Trade date
Nov 5, 2026
7:14 AM ET 8-K
Financial Results

Xeris Biopharma Holdings Financial Results

Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.

“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”

John Shannon, Chairman and Chief Executive Officer

“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”

John Shannon, Chairman and Chief Executive Officer
4:59 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock

Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).

Value
$51.2K
Shares
5,000
Price
$10.23
Holding change
-0.4%
Trade date
Nov 2, 2026
4:58 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock

Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).

Value
$256K
Shares
25,000
Price
$10.23
Holding change
-2.2%
Trade date
Nov 2, 2026
4:57 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock

Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).

Value
$153K
Shares
15,000
Price
$10.23
Holding change
-0.9%
Trade date
Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.